WallStreetZenWallStreetZen

NYSEMKT: CCEL
Cryo Cell International Inc Stock Forecast, Predictions & Price Target

OverviewForecast
EarningsRevenueDividendOwnership

Analyst price target for CCEL

Based on 1 analyst offering 12 month price targets for Cryo Cell International Inc

Min Forecast
$8.50+53.15%
Avg Forecast
$8.50+53.15%
Max Forecast
$8.50+53.15%

Should I buy or sell CCEL stock?

Based on 1 analyst offering ratings for Cryo Cell International Inc.

Strong Buy
Strong Buy
1 analysts 100%
Buy
0 analysts 0%
Hold
0 analysts 0%
Sell
0 analysts 0%
Strong Sell
0 analysts 0%

Be the first to know when Wall Street analysts revise their CCEL stock forecasts and price targets.

CCEL stock forecasts by analyst

Analyst / FirmRatingActionPrice TargetUpside/DownsideDateAnalyst Color
lockedlocked$00.00+00.00%2025-03-04

1 of 1

Forecast return on equity

Is CCEL forecast to generate an efficient return?

Forecast return on assets

Is CCEL forecast to generate an efficient return on assets?

CCEL revenue forecast

What is CCEL's revenue in the next 1 years based on estimates from 1 analyst?

Avg 1 year Forecast
$32.2M+0.3%

CCEL vs Medical Care Facility Stocks

TickerPricePrice TargetUp/downsideConsensus
CCEL$5.55$8.50+53.15%Strong Buy
PIII$8.67$16.25+87.43%Buy
CCM$4.26N/AN/A
AMS$2.66N/AN/A
MODV$1.00$6.50+550.00%Buy
View Top Medical Care Facility Stocks

Cryo Cell International Stock Forecast FAQ

Is Cryo Cell International Stock a good buy in 2025, according to Wall Street analysts?

The consensus among 1 Wall Street analyst covering (NYSEMKT: CCEL) stock is to Strong Buy CCEL stock.

Out of 1 analyst, 1 (100%) are recommending CCEL as a Strong Buy, 0 (0%) are recommending CCEL as a Buy, 0 (0%) are recommending CCEL as a Hold, 0 (0%) are recommending CCEL as a Sell, and 0 (0%) are recommending CCEL as a Strong Sell.

If you're new to stock investing, here's how to buy Cryo Cell International stock.

What is CCEL's revenue growth forecast for 2025-2025?

(NYSEMKT: CCEL) Cryo Cell International's forecast annual revenue growth rate of N/A is not forecast to beat the US Medical Care Facilities industry's average forecast revenue growth rate of N/A, and while it is not forecast to beat the US market's average forecast revenue growth rate of N/A.

Cryo Cell International's revenue in 2025 is $32,102,751.

In 2025, CCEL is forecast to generate $260,245,520 in revenue, with the lowest revenue forecast at $260,245,520 and the highest revenue forecast at $260,245,520.

What is CCEL's forecast return on assets (ROA) for 2025-2025?

(NYSEMKT: CCEL) forecast ROA is N/A, which is lower than the forecast US Medical Care Facilities industry average of 7.73%.

What is CCEL's Price Target?

According to 1 Wall Street analyst that have issued a 1 year CCEL price target, the average CCEL price target is $8.50, with the highest CCEL stock price forecast at $8.50 and the lowest CCEL stock price forecast at $8.50.

The Wall Street analyst predicted that Cryo Cell International's share price could reach $8.50 by Mar 4, 2026. The average Cryo Cell International stock price prediction forecasts a potential upside of 53.15% from the current CCEL share price of $5.55.

What is CCEL's forecast return on equity (ROE) for 2025-2025?

(NYSEMKT: CCEL) forecast ROE is N/A, which is considered weak.
©2025 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.